menu
    • menu
    [{"orgOrder":0,"company":"WEX Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tetrodotoxin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"WEX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"WEX Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"WEX Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"WEX Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tetrodotoxin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"WEX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"WEX Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"WEX Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"WEX Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Merger","leadProduct":"Tetrodotoxin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Dogwood Therapeutics \/ Wex Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Wex Pharmaceuticals"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tetrodotoxin","moa":"Sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dogwood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Tetrodotoxin

    Menu

    Tetrodotoxin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dogwood Therapeutics

                            U.S.A arrow
                            Biotech Digital Meet
                            Not Confirmed

                            Dogwood Therapeutics

                            U.S.A arrow
                            Biotech Digital Meet
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrodotoxin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dogwood Therapeutics Announces Dosing in Phase 2b Trial of Halneuron® for CINP

                            Details : Halneuron (tetrodotoxin injectable formulation) is a selective sodium channel blocker, produces analgesia, being developed chemotherapy induced neuropathic pain.

                            Product Name : Halneuron

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 21, 2025

                            Lead Product(s) : Tetrodotoxin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dogwood Therapeutics

                            U.S.A arrow
                            Biotech Digital Meet
                            Not Confirmed

                            Dogwood Therapeutics

                            U.S.A arrow
                            Biotech Digital Meet
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrodotoxin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : WEX Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Virios Therapeutics And Wex Pharmaceuticals Form Dogwood Therapeutics

                            Details : The combined company will be focused on Halneuron, in Phase 2b for chemotherapy-induced neuropathic pain, IMC-1, poised for Phase 3 for fibromyalgia and IMC-2 to treat Long-COVID sequelae.

                            Product Name : Halneuron

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 07, 2024

                            Lead Product(s) : Tetrodotoxin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : WEX Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            WEX Pharmaceuticals

                            Canada arrow
                            Biotech Digital Meet
                            Not Confirmed

                            WEX Pharmaceuticals

                            Canada arrow
                            Biotech Digital Meet
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrodotoxin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Wex Pharmaceuticals Inc. Commences Its Quantitative Sensory Testing Clinical Trial Evaluating the Impact of Ha...

                            Details : Halneuron (tetrodotoxin injectable formulation), a selective sodium channel blocker, produces analgesia either by decreasing the propagation of action potentials by sodium channels, being developed for Neuropathic Pain.

                            Product Name : Halneuron

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 11, 2023

                            Lead Product(s) : Tetrodotoxin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            WEX Pharmaceuticals

                            Canada arrow
                            Biotech Digital Meet
                            Not Confirmed

                            WEX Pharmaceuticals

                            Canada arrow
                            Biotech Digital Meet
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrodotoxin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Wex Pharmaceuticals Inc. Enrolls the First Patient in the Phase 2b Clinical Trial Evaluating the Efficacy and ...

                            Details : Halneuron (Tetrodotoxin injectable formulation), a selective sodium channel blocker, produces analgesia either by decreasing the propagation of action potentials by sodium channels and/or by blocking ectopic discharges associated with chronic pain.

                            Product Name : Halneuron

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 03, 2023

                            Lead Product(s) : Tetrodotoxin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth